Stock Price Quote

EMMESSAR BIOTECH & NUTRITION LTD.

NSE : NABSE : 524768ISIN CODE : INE634B01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE23.68-0.36 (-1.5 %)
PREV CLOSE ( ) 24.04
OPEN PRICE ( ) 25.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 735
TODAY'S LOW / HIGH ( )23.41 25.15
52 WK LOW / HIGH ( ) 18.4242.75
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992
Management Info
- Chairman Srinivasa Raghavan Mathurakavi Ayyangar - Managing Director
Registered Office

Address Plot No. T-3/2,M I D C Area,Taloja,
Raigad Dist,
Maharashtra-410208

Phone 022-35661373 / 35664530

Email enquiries@ebnl.org

Website www.ebnl.org

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE

NEWS

13May Emmessar Biotech & Nutrition informs a
Emmessar Biotech & Nutrition has informed that it enclosed copies of..
05May Emmessar Biotech & Nutrition informs a
Emmessar Biotech & Nutrition has informed that a meeting of the Boar..
30Mar Emmessar Biotech & Nutrition informs a
Emmessar Biotech & Nutrition has informed that pursuant to clause 4..
02Aug Emmessar Biotech & Nutrition informs a
Emmessar Biotech & Nutrition has informed, pursuant to Regulation 29..
24Apr Emmessar Biotech & Nutrition informs a
Emmessar Biotech & Nutrition has informed that the Board of Director..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit1.34.37
Gross Profit 1.62 5.81
Operating Profit 1.866.83
Net Sales 0.593.71

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kwality Pharma (BSE)
peergroup  3444.75 (3.53%)
M.Cap ( in Cr)3574.34
Neuland Laboratories (BSE)
peergroup  23311.50 (0.38%)
M.Cap ( in Cr)29908.40
Ajanta Pharma (BSE)
peergroup  3675.15 (1.64%)
M.Cap ( in Cr)45924.32
Fredun Pharma (BSE)
peergroup  1547.75 (3.33%)
M.Cap ( in Cr)2559.68
Venus Remedies (BSE)
peergroup  1786.80 (2.86%)
M.Cap ( in Cr)2388.41

Shareholding Pattern

PROMOTERS 59.53%
NON-INSTITUTION 40.28%
FI/BANKS/INSURANCE 0.14%
MUTUAL FUNDS/UTI 0.05%
GOVERNMENT 0%
FII 0%

About

no data found

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.